Research Article
Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
Table 1
Patient characteristics.
| Characteristics | Number of patients | Percent (%) |
| Age (years), median (range) | 50 (26–70) | | Gender | | | Male/female | 25/10 | 71.4/28.6 | ECOG performance status | | | 0/1/2 | 10/23/2 | 28.6/65.7/5.7 | Primary tumour location | | | Upper 1/3 (cardia/fundus) | 3 | 8.3 | Mid 1/3 (body) | 17 | 47.2 | Lower 1/3 (antrum/pylorus) | 9 | 25.0 | Diffuse (entire stomach) | 5 | 13.9 | Unknown | 1 | 5.6 | Site of metastasis | | | Nodal, distant | 29 | 82.9 | Peritoneum | 19 | 54.3 | Liver | 9 | 25.7 | Lung | 4 | 11.4 | Pancreas | 3 | 8.6 | Bone | 3 | 8.6 | Ureter | 3 | 8.6 | Ovary | 2 | 5.7 | Pleura | 2 | 5.7 | Number of metastatic sites | | | 3/3 | 19/16 | 54.3/45.7 | Histology | | | Adenocarcinoma, well differentiated | 4 | 11.4 | Adenocarcinoma, moderately differentiated | 7 | 20 | Adenocarcinoma, poorly differentiated | 17 | 48.6 | Signet ring cell | 5 | 14.3 | Unclassified | 2 | 5.7 | Disease status | | | Initially metastatic/recurrent | 27/8 | 77.1/22.9 | CEA level | | | Normal/elevated/unknown | 15/19/1 | 42.9/54.3/2.8 | Haemoglobin level | | | Normal/decreased | 14/21 | 40.0/60.0 | Surgery | | | Gastrectomy/no gastrectomy | 11/24 | 31.4/68.6 | First-line regimen | | | DS/DOS | 9/26 | 25.7/74.3 | Progressive disease after first-line chemotherapy | | | During or 3 months after end of treatment | 23 | 65.7 | 3 months after end of treatment | 12 | 34.3 |
|
|
DS: docetaxel plus S-1; DOS: docetaxel plus S-1 with oxaliplatin; ECOG: Eastern Cooperative Oncology Group; CEA: carcinoembryonic antigen.
|